Boston Scientific (BSX) Could Be 11% Undervalued On Recalls And Lowered Guidance

Boston Scientific (BSX) is under renewed scrutiny after voluntary Class II recalls affecting its Direxion Torqueable Microcatheter products and a recent Nalu Neurostimulation System issue, alongside lower guidance following Q2 and Q3 earnings updates.

Despite the recalls and trimmed guidance, Boston Scientific’s share price has shown short bursts of strength, with a 7 day share price return of 3.72% and a 30 day share price return of 3.12%. However, the 90 day share price return has declined 14.45% and the year to date share price return is down 53.18%, feeding into a 1 year total shareholder return that has fallen 56.82% and a 3 year total shareholder return that is down 18.40%. Momentum has clearly faded even as fresh product data and partnerships arrive.

Compare how Boston Scientific stacks up against other medical device stocks under pressure from recalls and guidance resets by scanning the hand picked 31 resilient stocks with low risk scores in minutes.

Boston Scientific still looks like a substantial medical technology platform, yet the share price reset and recall overhang now raise a sharper question. Are investors paying a fair price for that strength today, or a premium they may later question?

Most Popular Narrative: 11% Undervalued

Boston Scientific’s analyst consensus Narrative on Simply Wall St places fair value at $49.60 per share compared with a last close of $44.34. This frames the recalls and guidance reset against a market that already prices in some of the bad news while still assigning value to longer term earnings power. That spread sits on top of a 7.84% discount rate that analysts use to bring future cash flows back to today’s dollars.

The main factor that has to go right is that interventional cardiology and vascular therapies continue to grow solidly and that acquisitions like Penumbra and the MiRus TAVR option integrate effectively enough to offset weaker EP and LAAC demand and the impact of the cyberattack.

The current valuation implies the market is discounting the shares for near term growth and margin pressure more than this narrative judges warranted, given the planned restructuring savings, capital returns, and expansion into large adjacencies. Based on this view, Boston Scientific is considered undervalued with a positive outlook.

See why 90 investors see Boston Scientific as 11% undervalued.

Result: Fair Value of $49.60 (UNDERVALUED)

Still, the narrative around Boston Scientific can crack if prolonged weakness in electrophysiology and WATCHMAN persists, or if the large Penumbra deal delivers slower than expected benefits.

Find out about the key risks to this Boston Scientific narrative.

Next Steps

Boston Scientific splits opinion right now, with clear concerns sitting alongside real strengths. If you want a sharper view of both sides, move fast and weigh the balance of 4 key rewards and 1 important warning sign.

Looking for more Boston Scientific sized opportunities?

Do not stop with Boston Scientific. Use the Simply Wall St Screener to spot fresh ideas that fit your style before the crowd catches on.

• Target resilient cash generators by starting with a list of solid balance sheet and fundamentals (24 results) that can better withstand shocks and funding stress.
• Hunt for mispriced potential and let the 32 high quality undervalued stocks highlight businesses where fundamentals and market expectations do not fully line up.
• Scout for early stage potential and use the 13 elite penny stocks with strong financials to narrow tiny listings with stronger financial underpinnings.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com